Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.

Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Billiet I, Torecilla JL, Pfeffer R, Cutajar CL, Van der Kwast T, Collette L.

Lancet Oncol. 2010 Nov;11(11):1066-73. doi: 10.1016/S1470-2045(10)70223-0. Epub 2010 Oct 7.

PMID:
20933466
2.

Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study.

Spry NA, Galvão DA, Davies R, La Bianca S, Joseph D, Davidson A, Prince R.

BJU Int. 2009 Sep;104(6):806-12. doi: 10.1111/j.1464-410X.2009.08458.x. Epub 2009 Mar 5.

3.

Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer.

Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM, Shipley WU.

J Clin Oncol. 2008 May 20;26(15):2497-504. doi: 10.1200/JCO.2007.14.9021. Epub 2008 Apr 14.

PMID:
18413638
4.

Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.

Roach M 3rd, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, Lawton C, Valicenti R, Grignon D, Pilepich MV.

J Clin Oncol. 2008 Feb 1;26(4):585-91. doi: 10.1200/JCO.2007.13.9881. Epub 2008 Jan 2.

PMID:
18172188
5.

Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions.

D'Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, Joseph D, Tai KH, Malone S, Ludgate C, Steigler A, Kantoff PW.

J Clin Oncol. 2007 Jun 10;25(17):2420-5.

PMID:
17557956
6.

Endocrine complications of androgen-deprivation therapy in men with prostate cancer.

Harle LK, Maggio M, Shahani S, Braga-Basaria M, Basaria S.

Clin Adv Hematol Oncol. 2006 Sep;4(9):687-96. Review.

PMID:
17099626
7.

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.

Keating NL, O'Malley AJ, Smith MR.

J Clin Oncol. 2006 Sep 20;24(27):4448-56.

PMID:
16983113
8.

Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression.

Higano C, Shields A, Wood N, Brown J, Tangen C.

Urology. 2004 Dec;64(6):1182-6.

PMID:
15596194
10.

Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial.

Green HJ, Pakenham KI, Headley BC, Yaxley J, Nicol DL, Mactaggart PN, Swanson C, Watson RB, Gardiner RA.

BJU Int. 2002 Sep;90(4):427-32.

12.

Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations.

Bruchovsky N, Klotz LH, Sadar M, Crook JM, Hoffart D, Godwin L, Warkentin M, Gleave ME, Goldenberg SL.

Mol Urol. 2000 Fall;4(3):191-9;discussion 201.

PMID:
11062374
13.

Clinical Experience with Intermittent Androgen Suppression in Prostate Cancer: Minimum of 3 Years' Follow-Up.

Goldenberg SL, Gleave ME, Taylor D, Bruchovsky N.

Mol Urol. 1999;3(3):287-292.

PMID:
10851335
14.

Intermittent androgen suppression in the management of prostate cancer.

Crook JM, Szumacher E, Malone S, Huan S, Segal R.

Urology. 1999 Mar;53(3):530-4.

PMID:
10096379
15.

A pilot study of intermittent androgen deprivation in advanced prostate cancer.

Horwich A, Huddart RA, Gadd J, Boyd PJ, Hetherington JW, Whelan P, Dearnaley DP.

Br J Urol. 1998 Jan;81(1):96-9.

PMID:
9467483
16.

Interpreting the significance of changes in health-related quality-of-life scores.

Osoba D, Rodrigues G, Myles J, Zee B, Pater J.

J Clin Oncol. 1998 Jan;16(1):139-44.

PMID:
9440735
17.
18.
19.

Intermittent endocrine therapy of prostate cancer.

Tunn UW.

Eur Urol. 1996;30 Suppl 1:22-5; discussion 38-9.

PMID:
8977986
20.

Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study.

Higano CS, Ellis W, Russell K, Lange PH.

Urology. 1996 Nov;48(5):800-4.

PMID:
8911533

Supplemental Content

Support Center